Samsung Biologics Co Ltd stock (KR7207940008): earnings momentum and biotech manufacturing scale

Samsung Biologics Co Ltd has expanded capacity and reported solid 2024 results, underscoring its role as a major global contract manufacturer for biopharmaceuticals with relevance for US drug developers and investors.

Samsung Biologics Co Ltd has continued to expand its manufacturing scale while reporting higher revenue and operating profit for 2024, highlighting its position as a major contract development and manufacturing organization (CDMO) serving global biopharma clients, according to a full-year earnings release published on January 24, 2025 by Samsung Biologics.

As of: 05/16/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Samsung Biologics
• Sector/industry: Biopharmaceutical contract development and manufacturing (CDMO)
• Headquarters/country: Incheon, South Korea
• Core markets: Global biopharma outsourcing for biologic drugs, including US and European clients
• Key revenue drivers: Manufacturing and development services for monoclonal antibodies and other biologic therapies
• Home exchange/listing venue: Korea Exchange (KRX)
• Trading currency: South Korean won (KRW)

Samsung Biologics: core business model

Samsung Biologics focuses on providing contract manufacturing, development, and related services for biologic medicines to pharmaceutical and biotechnology companies worldwide. The company operates as a pure-play CDMO, meaning that it does not market its own branded drugs but instead produces therapies on behalf of its clients. This model allows customers to outsource complex large-molecule production while retaining product ownership and commercialization rights.

The group’s operations are centered at the Bio Campus in Songdo, Incheon, where it runs multiple large-scale manufacturing plants designed for monoclonal antibodies and other biologic modalities. By offering services from cell line development and process optimization through to commercial-scale production and fill-finish, Samsung Biologics aims to be a one-stop partner for companies seeking to bring biologic drugs to market. This full-service approach is particularly relevant for smaller biotechnology firms that may lack internal manufacturing capabilities.

Revenue is predominantly generated through long-term contracts that cover clinical and commercial production for a range of biologic products, including therapies targeted at oncology, immunology, and chronic diseases. As the global pharmaceutical industry continues to shift toward biologic and biosimilar drugs, the demand for scalable and reliable manufacturing capacity has increased, creating a favorable backdrop for CDMOs such as Samsung Biologics, according to the company’s description of its business model on its website as of February 2025.

Main revenue and product drivers for Samsung Biologics Co Ltd

In its 2024 annual results, Samsung Biologics reported consolidated revenue of approximately 4.15 trillion South Korean won and operating profit of around 1.58 trillion won for the year ended December 31, 2024, according to a results announcement dated January 24, 2025 on the company’s investor relations site. The company stated that revenue growth was supported by increased utilization of existing plants and the contribution from new capacity that entered service during the reporting period, as outlined in the same release by Samsung Biologics as of 01/24/2025.

A central revenue driver is the high-volume production of monoclonal antibody therapies under multi-year contracts. These contracts can provide a relatively visible revenue stream, although actual volumes may vary depending on client demand and the lifecycle of the underlying medicines. In addition to commercial production, the company generates income from clinical-scale batches and process development services, which can be important in building future commercial relationships as client products advance through late-stage trials.

Samsung Biologics has also emphasized expansions in capacity, including its so-called Plant 4, which it describes as one of the world’s largest single-site biologics production facilities. The ramp-up of this plant, along with additional investment in development capabilities, is expected by the company to support further revenue growth by enabling it to serve more projects and larger individual contracts. For US investors, this scale can be relevant because many US-based biotechnology and pharmaceutical companies seek large, compliant, and cost-efficient production partners for their biologic portfolios.

Industry trends and competitive position

The biologics CDMO industry has expanded rapidly over the past decade as more therapies are developed as large-molecule drugs. Industry research firms have noted that global spending on biologic medicines continues to grow faster than the overall pharmaceutical market, driven by targeted treatments and complex modalities. This shift encourages both large pharmaceutical groups and smaller biotechnology companies to outsource manufacturing to specialized providers with established quality systems and global regulatory track records.

Samsung Biologics competes with other global CDMOs that also specialize in biologics, including firms with facilities in North America, Europe, and Asia. The company’s competitive positioning is largely tied to its manufacturing scale, cost structure, and ability to win long-term contracts from global clients. Its location in South Korea offers proximity to fast-growing Asian markets, while its client base includes numerous US and European drug developers that require reliable supply into developed markets. Regulatory approvals for its plants from agencies such as the US Food and Drug Administration and the European Medicines Agency support its role in worldwide supply chains.

Another aspect of the company’s competitive profile is its focus on integrating development and manufacturing services, which can help clients transition from clinical to commercial production without changing suppliers. This can be particularly important for smaller US biotechnology companies that prioritize speed and continuity as they approach potential product launches. For US investors, the combination of scale, regulatory track record, and long-term contracts may be key factors when considering how the company fits within the broader global CDMO landscape.

Why Samsung Biologics Co Ltd matters for US investors

Samsung Biologics plays a role in the supply chain for biologic therapies that are marketed or developed in the United States, even though the company’s primary listing is on the Korea Exchange and its revenues are denominated in won. Many US-based pharmaceutical and biotechnology firms rely on external manufacturing partners for biologics, and Samsung Biologics positions itself as one of the large-scale providers capable of supplying global markets, including the US. This indirect exposure to US healthcare spending can be relevant for investors who track the global biopharma ecosystem.

For US investors, the company’s performance is influenced not only by local Korean market conditions but also by global demand for biologics, regulatory developments in key markets, and the success of its clients’ drug pipelines. In particular, the US remains the largest market for innovative therapies, which means that regulatory approvals, reimbursement trends, and competitive dynamics in the US can affect the production volumes that CDMOs deliver. Investors based in the US who follow the biopharmaceutical sector may therefore watch Samsung Biologics as part of a broader view on outsourced manufacturing capacity and biologics supply chains.

Currency movements between the South Korean won and the US dollar, as well as differences in market structure between the Korea Exchange and US exchanges, can also play a role in how US investors assess the company. While the stock is not primarily traded on US venues, it can still be accessed via certain international brokerage platforms that provide exposure to South Korean equities. This cross-border dimension adds another layer of consideration for investors analyzing how a large Asian CDMO fits into a diversified health care or biotechnology-related portfolio.

Conclusion

Samsung Biologics Co Ltd has expanded its manufacturing footprint and reported higher revenue and operating profit for 2024, underscoring its role as a major player in the biologics CDMO industry. The company’s focus on large-scale monoclonal antibody production and integrated development services positions it to benefit from the ongoing shift toward biologic therapies worldwide. For US investors, Samsung Biologics offers indirect exposure to the growth of biologic medicines and outsourced manufacturing, though considerations such as currency risk, regulatory environments, and the performance of its global client base remain important. As with any stock, prospective investors may wish to evaluate how the company’s capacity expansions, contract pipeline, and competitive landscape fit with their broader view of the healthcare and biotechnology sectors.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.